Evidence-Based Complementary and Alternative Medicine / 2015 / Article / Tab 5 / Review Article
Effects of Whole-Body Vibration Therapy in Patients with Fibromyalgia: A Systematic Literature Review Authors Reference Instrument Outcome measure CG baseline CG after treatment EG baseline EG after treatment Treatment effect Reported effect Alentorn-Geli et al.
[27 ] ELISA IGF-1 NR NR NR NR NR =
[29 ] FIQ Functional capacity NR NR NR NR NR Δ 100 mm VAS Pain NR NR NR NR NR Δ ↑ Fatigue NR NR NR NR NR Δ ↑ Stiffness NR NR NR NR NR ↑ Depression NR NR NR NR NR = Gusi et al.
[31 ] FIQ Functional capacity 53.6 ± 12.3 * 57.5 ± 11.2 * 59.3 ± 9.8 * 56.7 ± 11.1 * −6.42 * ↑ 15D questionnaire Quality of life 0.65 ± 0.1 NR 0.63 ± 0.1 NR NR =
[30 ] Biodex Balance System Dynamic balance 1.47 ± 0.55 * 1.51 * 1.49 ± 0.67 * 0.85 * −0.69 * ↑
[32 ] Biodex Balance System SB overall SI (°) 1.36 ± 0.50 1.40 ± 0.50 1.53 ± 0.56 0.88 ± 0.41 −0.65 ↑ SB anteroposterior SI (°) 0.80 ± 0.29 0.96 ± 0.47 1.05 ± 0.49 0.56 ± 0.31 −0.64 ↑ SB mediolateral SI (°) 0.94 ± 0.37 0.83 ± 0.26 0.88 ± 0.37 0.55 ± 0.22 −0.19 = Sañudo et al.
[34 ] T-Force Dynamic Measurement System Knee extensor strength 207.4 ± 16.5 202.6 ± 13.6 208.2 ± 16.7 210.7 ± 18.1 7.3 = Biodex Balance System OE overall SI 7.50 ± 3.07 6.47 ± 2.98 6.63 ± 3.23 5.5 ± 2.67 −0.1 = OE mean deflection 6.25 ± 2.93 5.63 ± 2.86 5.52 ± 2.87 4.66 ± 2.55 −0.2 = OE anteroposterior SI 5.42 ± 2.13 5.33 ± 2.68 4.97 ± 2.45 4.76 ± 2.81 −0.1 = OE anteroposterior mean deflection 2.93 ± 1.37 3.48 ± 2.64 2.90 ± 1.79 3.60 ± 2.81 0.2 = OE mediolateral SI 5.07 ± 2.57 3.35 ± 1.97 4.34 ± 2.32 2.49 ± 1.09 −0.1 ↑ OE mediolateral mean deflection 1.61 ± 1.18 1.23 ± 0.93 1.28 ± 1.04 1.17 ± 0.75 0.3 = CE overall SI 11.67 ± 2.41 11.37 ± 2.32 11.9 ± 2.16 10.7 ± 2.64 −0.9 = CE mean deflection 10.35 ± 2.25 9.90 ± 2.30 10.51 ± 2.14 9.26 ± 2.57 −0.8 = CE anteroposterior SI 8.97 ± 1.88 8.86 ± 2.40 9.37 ± 2.25 8.75 ± 2.93 −0.5 = CE anteroposterior mean deflection 4.12 ± 2.41 3.74 ± 2.28 4.25 ± 2.36 5.01 ± 3.71 1.1 = CE mediolateral SI 7.37 ± 2.30 6.25 ± 2.05 7.47 ± 1.28 5.56 ± 1.38 −0.8 ↑ CE mediolateral mean deflection 2.55 ± 1.49 2.01 ± 1.33 2.75 ± 1.31 2.01 ± 1.34 −0.2 =
[33 ] FIQ Functional capacity 56.66 ± 11.58 49.81 ± 14.87 48.89 ± 12.08 43.79 ± 12.31 1.7 Δ# SF-36 Quality of life 33.58 ± 12.10 42.51 ± 11.30 44.16 ± 18.88 54.00 ± 15.83 0.9 Δ↑# T-Force System Maximum power of knee extensor muscles 80.92 ± 24.17 85.01 ± 19.73 81.29 ± 28.34 87.05 ± 19.72 1.7 = Number of repetitions 22.08 ± 9.21 24.71 ± 6.26 23.75 ± 7.87 28.71 ± 5.25 2.3 Δ Muscular fatigue index 0.91 ± 0.14 0.96 ± 0.05 0.90 ± 0.06 0.97 ± 0.17 0.0 = Sañudo et al.
[28 ] Biodex Stability System OE overall SI 5.53 (1.49) 6.10 (1.40) 7.02 (3.66) 5.75 (2.51) −1.84 = OE mean deflection 4.58 (1.32) 4.99 (1.16) 5.85 (3.18) 4.67 (2.09) −1.59 = OE anteroposterior SI 4.46 (1.36) 5.03 (1.21) 5.36 (2.90) 4.92 (2.18) −1.01 = OE anteroposterior mean deflection 2.18 (1.67) 2.40 (1.08) 2.47 (2.24) 2.48 (1.29) −0.21 = OE mediolateral SI 3.35 (1.17) 3.83 (1.37) 4.54 (2.56) 2.94 (1.44) −2.08 Δ↑ OE mediolateral mean deflection 1.23 (1.66) 0.76 (0.19) 2.28 (1.08) 1.31 (0.21) −0.5 ↑ CE overall SI 9.31 (1.83) 8.89 (1.95) 9.91 (3.64) 9.10 (2.99) −0.39 = CE mean deflection 7.90 (1.77) 7.63 (1.80) 8.43 (3.55) 7.76 (2.83) −0.4 = CE anteroposterior SI 7.31 (1.93) 7.30 (1.84) 7.68 (2.58) 7.32 (2.47) −0.37 = CE anteroposterior mean deflection 3.21 (2.66) 3.87 (2.38) 1.90 (2.01) 3.18 (2.27) 0.62 = CE mediolateral SI 5.81 (1.49) 5.21 (1.21) 6.39 (2.86) 5.48 (2.03) −0.31 Δ CE mediolateral mean deflection 1.62 (1.02) 0.95 (0.84) 1.09 (0.87) 1.80 (1.02) 1.38 = T-Force System Number of repetitions 23.72 (7.98) 23.50 (6.63) 30.85 (8.90) 31.14 (7.18) 0.51 =
CG: control group; EG: exercise group; NR: not reported; ELISA: enzyme-linked immunosorbent assay; IGF-1: serum insulin-like growth factor-1; FIQ: fibromyalgia impact questionnaire; SB: static balance; VAS: visual analogue scale; OE: open eyes; CE: closed eyes; SI: stability index; =: no significant difference relative to baseline and/or the control group; ↑ : statistically significant improvement in the WBV group relative to the control group; Δ: statistically significant improvement in the WBV group relative to baseline; #: statistically significant improvement in the control group relative to baseline.
